Abstract library

354 results for "Adrenocortical carcinoma".
#64 Sustained response to anti IGFR-1R monoclonal antibody combined with docetaxel in a patient with metastatic adrenocortical carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Treatment results in advanced disease are disappointing and median survival is less than 12 months. There is no standard chemotherapy, even though mitotane and cisplatin-based regimens are frequently used with limited efficacy. In vitro data suggest that overexpressed insulin growth factor-2 (IGF-2) acting via the IGF-1 receptor (IGF-1R) is relevant for ACC and that the IGF-1R and 2R pathway is a promising target.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Sara De Dosso
#257 Doxorubicin, Etoposide and Cisplatin as first-line Treatment in Advanced Adrenocortical Carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis in advanced setting due to its low chemosensibility. Mitotane and cisplatin-based regimens are the most frequently used treatments.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#1641 Somatostatin Receptor Expression in Adrenocortical Carcinoma
Introduction: Adrenocortical carcinoma (ACC) is an uncommon neoplasm with an estimated annual incidence of 0.5-2 cases per million population. Surgery of the adrenal tumor is the major treatment. When complete tumor removal is not possible, or in case of recurrence, medical treatment with O,p’DDD(mitotane) is recommended. The treatment of ACC is currently based on the mitotane partial responses have been described in 19-34% of cases, and there are single reports of complete responses.The discovery of somatostatin (SST) and the identification of stable SST analogs with a longer half-life have raised new hopes for the treatment of endocrine tumors.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Iya A Voronkova
#1168 Simultaneous Large Cell Neuroendocrine Carcinoma and Adenocarcinoma of the Stomach: A Case Report and Literature Review
Introduction: Large cell neuroendocrine carcinoma (LCNEC) of the stomach is rare. Gastric NEC occasionally has another component, such as adenocarcinoma, in the same tumor. However, the concurrent occurrence of LCNEC and adenocarcinoma at different sites in the stomach is extremely rare.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Shoichi Nakazuru
#117 Synchronous appendiceal neuroendocrine carcinoma and mucinous cystadenocarcinoma: a case report
Introduction: Appendiceal tumors with histological features of both carcinoids and adenocarcinomas are very rare. Carcinomas of the appendix are usually mucinous adenocarcinomas with a tendency to produce peritoneal pseudomyxoma and without metastatic spread until late in the disease course. Carcinoid tumors of the appendix are a common incidental finding.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Sanja Ognjanovic
#1671 Gallbladder Neuroendocrine Carcinoma. Is It Different from Adenocarcinoma?
Introduction: Literature on Gallbladder neuroendocrine carcinoma is limited.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Assistant Profes Kalayarasan Raja
#66 Adrenocortical cancer: a therapeutic approach with everolimus (RAD001)
Introduction: Adrenocortical cancer (ACC) is a rare disease with very poor outcome. ACC responds poorly to standard chemotherapy. Mitotane, used as adjuvant therapy to surgery, prolongs recurrence-free survival, but the response is limited to 23% of patients and resistance occurs in the majority of patients (1). There is no curative therapy for ACC. Pre-clinical studies have shown involvement of both IGF-2/IGF-1R and Akt/mTOR pathways in ACC, and IGF-1R and mTOR inhibitors inhibited cell proliferation of human adrenocortical carcinoma cell lines in vitro (2,3,4).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maria Gueorguiev
#1163 Mitotane, Adrenolitic Drug, Inhibits Cell Survival and Function of Several Pituitary Cytotypes
Introduction: Mitotane (DDD) is an adrenolytic agent that is used for the treatment of adrenocortical carcinoma. We previously demonstrated that DDD affects thyrotrope cell viability and function. These data represent a possible explanation of the biochemical picture consistent with central hypothyroidism in patients undergoing DDD therapy. DDD also inhibits corticotrope cell viability by inducing caspase-mediated apoptosis and reduces POMC expression as well as basal and CRH-induced ACTH secretion. Cells originating from tissues different from pituitary are not sensitive to the inhibitory effects of DDD. Our data suggest that DDD inhibits cell survival and function of many pituitary cytotypes, acting with a generalized, but specific, toxic effect.
The majority of male patients undergoing adjuvant DDD therapy show a clinical picture of hypogonadism, characterized by low free testosterone and unmodified LH concentration
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Erica Gentilin
#1243 Neuroendocrine Carcinomas of the Prostate
Introduction: Since focal neuroendocrine (NE) differentiation in prostate carcinomas represents a frequent phenomenon when NE markers are used for documentation, NE carcinomas are extremely rare form of highly aggressive prostate tumors.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Professor Alis Dema
Authors: Dema A, Taban S, Anderco D, Bardan R, ...
#2131 Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma
Introduction: Primary gallbladder neuroendocrine carcinoma is a relatively rare disease.
Conference: 15th Annual ENETS conference (2018)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: Yefan Zhang
Authors: Zhang Y, Chen X, Wang Y, Zhao J, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.